Arbutus Biopharma Corporation ABUS
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -12.47%
- 1 year
- -13.02%
- Open
- 4.28
- Prev close
- 4.28
- Mkt cap
- 645.29M
- Vol
- 2.53M
- Avg vol
- 4.88M
- EPS
- 0.79
- P/E
- 5.33
- Div yield
- 0.00%
More statistics
- Low
- 4.14
- High
- 4.30
- Forward P/E
- -30.67
- Beta
- 0.62
- Short ratio
- 5.03
- Inst. own
- 72.71%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 16, 2026
- 50-d avg
- 4.79
- 200-d avg
- 4.52
- 1y target
- 5.46
5D chart
Signals (56)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 29, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 28, 3:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:55 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:50 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 11:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 27, 3:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 26, 3:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:10 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 1:25 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:50 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 10:40 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 26, 9:35 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 9:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 23, 3:30 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 1:20 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 1:15 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:35 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:20 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:15 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:10 PM | 1 week ago |
| SMA: Bullish | Oct 23, 10:30 AM | 1 week ago |
News
1 week ago benzinga.com
FDA Lifts Three-Year Freeze On Arbutus Biopharma's Hepatitis B Study
The FDA lifts its 3-year clinical hold on Arbutus Biopharma's AB-101 hepatitis B drug candidate, clearing US clinical trials.
-
1 week ago benzinga.com
Arbutus Biopharma Says FDA Lifts Clinical Hold On AB-101 IND, Company May Now Engage In Additional Clinical Development For AB-101 In US
Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the Company was notified by the
1 week ago globenewswire.com
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease,…
3 weeks ago seekingalpha.com
Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure
Arbutus Biopharma is rated Buy, leveraging a $179.1M Moderna settlement and a 46M share buyback to enhance per-share value. Imdusiran, ABUS's RNAi asset for chronic hepatitis B, targets a functional…
4 weeks ago defenseworld.net
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Up 5.3% – Here’s What Happened
Arbutus Biopharma Corporation (NASDAQ: ABUS - Get Free Report) shot up 5.3% during mid-day trading on Wednesday. The company traded as high as $4.93 and last traded at $4.9370. Approximately…
1 month ago globenewswire.com
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease,…
1 month ago globenewswire.com
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious…
1 month ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
2 months ago defenseworld.net
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 130,023 Arbutus Biopharma Corporation $ABUS
Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Arbutus Biopharma Corporation (NASDAQ: ABUS) in the second quarter, according to its most recent disclosure with…
2 months ago defenseworld.net
Bank of America Corp DE Has $7.58 Million Stock Position in Arbutus Biopharma Corporation $ABUS
Bank of America Corp DE lowered its stake in Arbutus Biopharma Corporation (NASDAQ: ABUS) by 8.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange…
2 months ago globenewswire.com
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease,…
2 months ago benzinga.com
Why Is Arbutus Biopharma Stock Gaining Friday?
Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.
-
2 months ago benzinga.com
Arbutus Biopharma Plans To Commence Modified Dutch Auction Tender Offer To Repurchase Up To $230M Of Common Shares At Purchase Price Of Between $5.00 And $5.75 Per Share In Cash
Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified "Dutch
2 months ago globenewswire.com
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease,…
2 months ago defenseworld.net
Head-To-Head Comparison: YD Bio (NASDAQ:YDES) versus Arbutus Biopharma (NASDAQ:ABUS)
Arbutus Biopharma (NASDAQ: ABUS - Get Free Report) and YD Bio (NASDAQ: YDES - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two…
-
2 months ago benzinga.com
Arbutus Biopharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.014M Beat $700.000K Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 400 percent decrease over earnings of…
2 months ago globenewswire.com
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026
2 months ago businesswire.com
GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue
CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced the launch of Invenia™ ABUS (Automated Breast Ultrasound) Prime and ABUS StreamVue™, a redesigned enterprise viewer that recently received U.S.…
-
3 months ago benzinga.com
Arbutus Biopharma Announces Filing Of Three International Lawsuits Seeking To Enforce Patents Protecting LNP Technology Against Pfizer, BioNTech And Certain Of Their Affiliates
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle ("LNP") technology against Pfizer and…
3 months ago globenewswire.com
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and…
3 months ago seekingalpha.com
Arbutus Biopharma: Moderna Validates My IP Bull Case
Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS' in-house assets, I think Imdusiran has shown durable viral control. The main caveat…
-
5 months ago benzinga.com
Arbutus Biopharma Q1 EPS $0.87 Beats $(0.04) Estimate, Sales $179.126M Beat $750.000K Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $(0.04) by 2275 percent. This is a 769.23 percent increase over losses of…
5 months ago globenewswire.com
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna
6 months ago benzinga.com
Europe Clears First Flu/COVID Combo Shot From Moderna
Moderna stock rises after EU approval of flu-COVID combo vaccine mCOMBRIAX, backed by Phase 3 data showing strong immune response.
6 months ago benzinga.com
QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures up, QuidelOrtho shares down in pre-market trading. Allbirds, MIND, Arbutus Biopharma among other stocks also falling.
6 months ago benzinga.com
Why J B Hunt Transport Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
J B Hunt Transport Services Inc (JBHT) stock rose in pre-market trading after beating earnings estimates. Gainers include CTNT, MYSE, WNW, MDCX, WSHP, MAMO, ALIT, HQ, and SLDP while XHG and BIRD were…
-
6 months ago benzinga.com
Arbutus Biopharma's Imdusiran Receives FDA's Fast Track Designation To Treat Chronic Hepatitis B
Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the U.S. Food and Drug…
6 months ago globenewswire.com
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:…
-
7 months ago benzinga.com
Arbutus Biopharma Q4 EPS $(0.01) Beats $(0.03) Estimate, Sales $1.051M Miss $1.233M Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 85.71 percent increase over losses of…
7 months ago globenewswire.com
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025
8 months ago benzinga.com
Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars
Moderna shares jump after a $950 million settlement over COVID-19 vaccine patents, easing investor concerns and clearing legal uncertainty.
8 months ago benzinga.com
Staar Surgical Posts Downbeat Q4 Results, Joins Webtoon Entertainment, Gitlab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Staar Surgical Posts Downbeat Q4 Results, Joins Webtoon Entertainment, Gitlab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
8 months ago benzinga.com
Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Box Inc (BOX) shares jump 6.2% in pre-market trading after beating earnings expectations with $305.88M in revenue and 49 cents per share earnings.
8 months ago wsj.com
Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant
The company will appeal to a federal circuit court to argue that it has limited liability due to its status as a government contractor.
-
8 months ago benzinga.com
Roivant Sciences' Subsidiary, Arbutus Biopharma Sign $2.25B Settlement With Moderna To Resolve All U.S., Global Enforcement Actions; Moderna To Pay $950M Upfront Payment To Genevant, Arbutus
Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant Sciences Ltd. (NASDAQ:ROIV),…
8 months ago accessnewswire.com
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026 District Court's Section 1498 decision to be appealed to the Federal…
8 months ago globenewswire.com
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is…
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
11 months ago benzinga.com
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target
Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.
-
11 months ago benzinga.com
Arbutus Biopharma Q3 EPS $(0.04) Misses $(0.03) Estimate, Sales $529.000K Miss $1.267M Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 60 percent increase over losses of…
-
1 year ago benzinga.com
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
-
2 years ago benzinga.com
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
-
2 years ago benzinga.com
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
-
3 years ago benzinga.com
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
-
3 years ago benzinga.com
Earnings Scheduled For May 4, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
-
3 years ago benzinga.com
Earnings Scheduled For March 2, 2023
Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.
-
3 years ago benzinga.com
Earnings Scheduled For November 9, 2022
Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly earnings at $0.11 per share on revenue of $103.46 million.
-
4 years ago benzinga.com
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
-
4 years ago benzinga.com
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday, 849 stocks hit new 52-week lows.